Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Salmonella typhi Ty21a antigens refer collectively to the array of bacterial components present in the live attenuated oral typhoid vaccine strain known as "Ty21a." This preparation contains all major surface structures and internal proteins typical for wild-type Salmonella enterica serovar Typhi except for the Vi capsular polysaccharide, which is absent in this strain. The main immunogenic components include lipopolysaccharide (LPS) O-antigen, flagellar H-d antigen, and other outer membrane proteins. Upon oral administration, these antigens stimulate both humoral and cell-mediated immune responses that mimic natural infection but without causing disease. The induced immunity involves gut-homing T cells and B cells that produce antibodies against S. Typhi LPS and other surface structures; these responses are associated with protection from subsequent exposure to virulent S. Typhi strains.
Induction of protective immune responses via presentation of multiple S. Typhi antigens to the host immune system
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Salmonella typhi Ty21a antigen.